key: cord-0784714-xmjqf7u0
authors: Evangelou, Nikos; Garjani, Afagh; dasNair, Roshan; Hunter, Rachael; Tuite-Dalton, Katherine A; Craig, Elaine M; Rodgers, William J; Coles, Alasdair; Dobson, Ruth; Duddy, Martin; Ford, David Vincent; Hughes, Stella; Pearson, Owen; Middleton, Linda A; Rog, David; Tallantyre, Emma Clare; Friede, Tim; Middleton, Rodden M; Nicholas, Richard
title: Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register
date: 2020-08-27
journal: J Neurol Neurosurg Psychiatry
DOI: 10.1136/jnnp-2020-324449
sha: c71b47c411f253f0a4a89ec517fde9789375e800
doc_id: 784714
cord_uid: xmjqf7u0

nan

. Disability was assessed using the last recorded web-based Expanded Disability Status Scale (webEDSS) or MS Impact Scale v2 (MSIS-29v2).

As of 24 April, out of 3910 participants, 237 (6.1% (95% CI 5.3% to 6.8%)) reported self-diagnosed COVID-19 among whom 54 (22.8% (17.5% to 28.2%)) also had a diagnosis by a healthcare professional based on symptoms and 37 (15.6% (11.2% to 20.6%)) a confirmed diagnosis by testing. Three participants reported hospitalisation due to COVID-19. No deaths were reported. Among 1283 siblings without MS, 79 (6.2%) had a reported diagnosis of COVID-19. Adjusting for age and gender, the likelihood of contracting COVID-19 in pwMS was similar to siblings (OR 1.180 (0.888 to 1.569)).

Seven hundred and fifty-nine of 3812 participants reported that they were self-isolating and that they had been self-isolating for at least 2 weeks before symptom onset if they had COVID-19. Of these, 2 (0.3% (0% to 0.7%)) had self-diagnosed COVID-19 whereas 137 of 3053 participants not self-isolating (4.5% (3.8% to 5.2%)) had the disease (p<0.001). Among participants with confirmed COVID-19, 94.6% (86.5% to 100%) were not self-isolating which was higher than those without the disease (79.9% (78.7% to 81.3%), p=0.023). Selfisolating participants were slightly older than those not self-isolating (p<0.001). A lower proportion of participants on DMTs were self-isolating compared with those not taking DMTs (18.1% (16.4% to 20%) vs 21.5% (19.6% to 23.3%), p=0.01). Rate of self-isolation in participants taking high-efficacy DMTs was similar to those not taking DMTs and higher than those taking moderate-efficacy DMTs (21.3% vs 21.4% and 16.5%, p=0.993 and p=0.014, respectively). More participants with progressive MS (PMS) were self-isolating compared with relapsingremitting MS (RRMS) (23.2% (21% to 25.3%) vs 17.9% (16.3% to 19.5%), p<0.001).

Using self-diagnosed and confirmed COVID-19 as outcomes, 3714 and 3618 participants were included in the regression analysis, respectively. Self-isolation predicted a lower likelihood of having selfdiagnosed COVID-19 (OR 0.064 (0.016 to 0.259)) but not confirmed COVID-19.

Participants on DMTs were less likely to have self-diagnosed COVID-19 (OR 0.640 (CI 0.428 to 0.957)), which remained significant after removing PostScript self-isolating participants (OR 0.633 (0.402 to 0.998)). High-efficacy DMTs reduced the likelihood of self-diagnosed COVID-19 compared with no DMTs (OR 0.540 (0.311 to 0.938)) but not compared with moderate-efficacy DMTs. There was no significant association between taking DMTs and having confirmed COVID-19. It was not possible to do a formal statistical test for the association between individual DMTs and COVID-19 due to small numbers (table 1) .

Younger age was associated with increased likelihood of having selfdiagnosed (OR 1.043 (1.022 to 1.064)) and confirmed (OR 1.048 (1.009 to 1.087)) COVID-19.

Participants with PMS were less likely to have self-diagnosed (OR 0.429 (0.241 to 0.763)) or confirmed (OR 0.119 (0.015 to 0.967)) COVID-19 compared with those with RRMS, but this effect disappeared after excluding participants who were self-isolating.

Including webEDSS (n=2808) and physical MSIS-29v2 (n=3192) as additional predictors in the analysis showed no significant association with the likelihood of contracting COVID-19.

The gender distribution was similar between participants with and without COVID-19. More participants with selfdiagnosed COVID-19 reported themselves as having any ethnicity other than white compared with those without the disease (6.9% (3.9% to 10.1%) vs 3.8% (3.2% to 4.4%), p=0.019). Gender and ethnicity did not affect the likelihood of having COVID-19.

We report initial findings of an ongoing community-based COVID-19 study in a large UK-wide population of pwMS which coincided with the peak of the COVID-19 outbreak in the UK. 1 We show that pwMS taking immunomodulatory treatments do not have an increased risk of contracting COVID-19. We did not find individual DMTs to be noticeably over-represented among pwMS with COVID-19.

The incidence of COVID-19 in our population of pwMS was not higher than that of the general population, 2 and pwMS were not at a higher risk of having COVID-19 compared with their siblings without MS. The low hospitalisation rate in our population is possibly due to its patient-reported nature where hospitalised pwMS would fail to respond to the surveys.

The observation that self-isolating pwMS had a lower risk of COVID-19 was not unexpected. We found older pwMS and those with PMS were less likely to have COVID-19. This could be because they were self-isolating more. Similar to previous reports, we found evidence that pwMS with any ethnicity other than white had a higher chance of contracting COVID-19, 3 but larger numbers are required to confirm this.

When this study launched, there was no accurate or accessible test to diagnose COVID-19. Therefore, we decided to set a diagnosis of COVID-19 made by participants, based on their symptoms, as the primary outcome of the study. This approach has also been adopted in other large-scale studies and is in line with the UK government policy not to seek medical advice for mild symptoms of COVID-19. 4 5 In conclusion, during a period with strict precautions in place to prevent the spread of COVID-19, pwMS and those taking DMTs are not at an increased risk of contracting the disease.

non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions

Coronavirus (COVID-19) in the UK

Rapid implementation of mobile technology for real-time epidemiology of COVID-19

Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities

Real-Time tracking of self-reported symptoms to predict potential COVID-19

Guidance for households with possible coronavirus (COVID-19) infection